Home / Others / Sanofi approaches an agreement of $ 11,400 million for Bioverativ: source

Sanofi approaches an agreement of $ 11,400 million for Bioverativ: source



  View of the company's logo at the general meeting of shareholders of Sanofi on May 4, 2016.

Vincent Isore | IP3 | Getty Images

View of the company's logo at Sanofi's general shareholders' meeting on May 4, 2016.

The French pharmaceutical company Sanofi is close to acquiring the biotech company Bioverativ for $ 105 per share, valuing the Hemophilia manufacturer at about $ 11.4 billion, according to a person familiar with the matter.


Source link